PMV Pharmaceuticals (NASDAQ:PMVP) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) posted its earnings results on Tuesday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.07, FiscalAI reports.

PMV Pharmaceuticals Stock Up 4.0%

Shares of PMV Pharmaceuticals stock traded up $0.06 during mid-day trading on Tuesday, reaching $1.45. 143,319 shares of the stock traded hands, compared to its average volume of 524,804. The stock has a market capitalization of $77.06 million, a PE ratio of -0.97 and a beta of 1.41. The business has a 50-day moving average of $1.44 and a 200 day moving average of $1.31. PMV Pharmaceuticals has a fifty-two week low of $0.81 and a fifty-two week high of $1.88.

Wall Street Analysts Forecast Growth

PMVP has been the subject of several recent research reports. Evercore upgraded PMV Pharmaceuticals to a “strong-buy” rating in a research report on Monday, April 13th. Weiss Ratings raised shares of PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, PMV Pharmaceuticals presently has an average rating of “Moderate Buy”.

Institutional Trading of PMV Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Shay Capital LLC purchased a new stake in shares of PMV Pharmaceuticals during the second quarter worth approximately $26,000. Squarepoint Ops LLC boosted its holdings in shares of PMV Pharmaceuticals by 101.8% during the 4th quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock worth $33,000 after purchasing an additional 13,367 shares during the last quarter. Public Employees Retirement System of Ohio boosted its stake in PMV Pharmaceuticals by 349.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock worth $34,000 after buying an additional 21,334 shares during the last quarter. Algert Global LLC purchased a new stake in shares of PMV Pharmaceuticals in the third quarter valued at about $87,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of PMV Pharmaceuticals in the 3rd quarter valued at approximately $96,000. 90.20% of the stock is owned by institutional investors and hedge funds.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.